Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608062 · ClinicalTrials.gov registry record · NA
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
A NA study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 155
- Enrollment target
NCT00608062: Completed NA study, sponsored by University of Colorado, Denver.
NCT00608062 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608062, a NA study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to find out why women's arteries stiffen as they go through menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with the loss of estrogen because of "oxidative stress," the production of molecules that can damage cells and tissues in the body, and because the arteries lose their ability to expand, or dilate.
Primary Outcome
Carotid artery compliance measured by carotid artery ultrasound and brachial artery blood pressure
Interventions
- DRUG Transdermal placebo patch
- DRUG GnRHant - Ganirelix acetate
- DRUG Transdermal estradiol patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-10-25 |
| Phase | NA |
What the finished NCT00608062 record still lists
NCT00608062 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Transdermal placebo patch is the first listed.
NCT00608062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608062 about?
NCT00608062 is a clinical study titled "Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women". The purpose of this study is to find out why women's arteries stiffen as they go through menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with the loss of estrogen because of "oxidative stress," the production of molecules that can damage cells and tissues in th...
What is the current status of trial NCT00608062?
This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2007-03. Estimated completion is 2012-10-25.
What interventions are being tested in trial NCT00608062?
The interventions under investigation include: Transdermal placebo patch (DRUG), GnRHant - Ganirelix acetate (DRUG), Transdermal estradiol patch (DRUG).
Who is sponsoring clinical trial NCT00608062?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608062's enrollment target sits among peer trials
155 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia